VeriChip shares jump after H1N1 patent license win

Shares of VeriChip Corp tripled after the company said it had been granted an exclusive license to two patents, which will help it to develop implantable virus detection systems in humans. The patents, held by VeriChip partner Receptors LLC, relate to biosensors that can detect the H1N1 and other viruses, and biological threats such as methicillin-resistant Staphylococcus aureus, VeriChip said in a statement. The technology will combine with VeriChip's implantable radio frequency identification devices to develop virus triage detection systems.